The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy

REFERENCES

• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS), adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304.
   PubMedGoogle Scholar
• Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301–1305.
   PubMed Web of Science ®Google Scholar
• Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004;91, S3–10.
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano Tet al,. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009;48:665–672.
   PubMed Web of Science ®Google Scholar
• Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91:S18–23.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Satoh H, Kurishima K, Nakamura R, Ishikawa H, Kagohashi Ket al,. Interstitial lung disease in patients with small cell lung cancer. Med Oncol 2010;27:763–767.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Yet al,. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 2011;6:1242–1246.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Azuma K, Sasada T, Okamoto M, Hattori S, Imamura Yet al,. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 2012;4:477–4782.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Yet al,. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer 2012;13:304–311.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Satoh H, Kurishima K, Nakamura R, Ishikawa H, Kagohashi Ket al,. Impact of interstitial lung disease on survival for patients with non-small cell lung cancer. Anticancer Res 2009;29:2671–2674.
   PubMed Web of Science ®Google Scholar
• Song DH, Choi IH, Ha SY, Han KM, Lee JJ, Hong MEet al,. Usual interstitial pneumonia with lung cancer: Clinicopathological analysis of 43 cases. Korean J Pathol 2014;48:10–16.
   PubMedGoogle Scholar
• Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203–216.
   PubMed Web of Science ®Google Scholar
• Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68–73.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kitamura S. KL-6: A serum marker for interstitial pneumonia. Chest 1995;108:311–315.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo Ket al,. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1680–1684.
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012;50:3–13.
   PubMedGoogle Scholar
• Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh Het al,. Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal 2010;24: 295–299.
   PubMed Web of Science ®Google Scholar
• Kannagi R, Fukushi Y, Tachikawa T, Noda A, Shin S, Shigeta Ket al,. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res 1986;46:2619–2626.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh Het al,. High serum concentrations of Sialyl Lewisx predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol 2006;13:1010–1018.
   PubMed Web of Science ®Google Scholar
• Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka Tet al,. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer 2007;58:369–75.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Kondo K, Ueda S, Hirasawa Y, Watanabe Ket al,. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology 1998;3:199–202.
   PubMedGoogle Scholar
• Satoh H, Kamma H, Ogata T, Yano H, Ohtsuka M, Hasegawa S. Clinical significance of serum levels of a carbohydrate antigen, sialyl SSEA-1, in patients with fibrosing lung disease. Am Rev Respir Dis 1991;144:1177–1181.
   PubMed Web of Science ®Google Scholar
• Kashiwabara K, Semba H, Fujii S, Tsumura S, Aoki R. Difference in benefit of chemotherapy between small cell lung cancer patients with interstitial pneumonia and non-small cell lung cancer patients. Anticancer Res 2015;35:1035–1071.
   Google Scholar
• Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012;6:63–74.
   PubMedGoogle Scholar
• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KKet al,. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: 788–824.
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Jret al,. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636–643.
   PubMed Web of Science ®Google Scholar
• Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:1652–1658.
   PubMed Web of Science ®Google Scholar
• Totani Y, Demur Y, Ameshima S, Ishizaki T, Miyamori I. The usefulness of serum KL-6 levels for the diagnosis of disease activity in idiopathic interstitial pneumonia. Nihon Kokyuki Gakkai Zasshi 2000;38:437–441 (in Japanese).
   PubMedGoogle Scholar
• Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. 2006;17:372–379.
   Google Scholar